^
    1d
    AQUILA: A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma (clinicaltrials.gov)
    P3, N=390, Completed, Janssen Research & Development, LLC | Active, not recruiting --> Completed
    Trial completion
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    4d
    A Study of Daratumumab (clinicaltrials.gov)
    P3, N=500, Recruiting, Janssen Research & Development, LLC | Trial completion date: Jan 2029 --> Dec 2029
    Trial completion date
    |
    lenalidomide • Darzalex (daratumumab) • carfilzomib • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • dexamethasone injection
    4d
    SCILLA: Self-administered Subcutaneous Daratumumab in Patients With Multiple Myeloma (clinicaltrials.gov)
    P4, N=50, Not yet recruiting, Odense University Hospital | Trial completion date: Jun 2027 --> Jan 2028 | Initiation date: Jan 2026 --> Aug 2026 | Trial primary completion date: Dec 2026 --> Jun 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    5d
    AQUARIUS: A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis (clinicaltrials.gov)
    P2, N=151, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: May 2025 --> Feb 2026
    Trial primary completion date
    |
    bortezomib • cyclophosphamide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • dexamethasone injection
    7d
    FIL_DALYA: Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. (clinicaltrials.gov)
    P2, N=28, Recruiting, Fondazione Italiana Linfomi - ETS | Trial primary completion date: Jan 2026 --> Jul 2027
    Trial primary completion date • IO biomarker
    |
    bortezomib • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    7d
    CEPHEUS: A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy (clinicaltrials.gov)
    P3, N=395, Completed, Janssen Research & Development, LLC | Active, not recruiting --> Completed
    Trial completion
    |
    lenalidomide • bortezomib • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    13d
    CEVOLUTION: Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma (clinicaltrials.gov)
    P3, N=380, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2029 --> Oct 2028
    Enrollment open • Trial primary completion date
    |
    carfilzomib • dexamethasone • pomalidomide • Empliciti (elotuzumab) • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • cevostamab (RG6160)
    14d
    Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial (clinicaltrials.gov)
    P2, N=74, Not yet recruiting, National Cancer Institute (NCI)
    New P2 trial
    |
    lenalidomide • carfilzomib • melphalan • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Tecvayli (teclistamab-cqyv) • Hemady (dexamethasone tablets) • plerixafor
    18d
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P1, N=258, Recruiting, Shanghai Henlius Biotech | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lenalidomide • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    25d
    Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure (clinicaltrials.gov)
    P2, N=74, Active, not recruiting, Eastern Cooperative Oncology Group | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    bortezomib • cyclophosphamide • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    26d
    DARANIVOVAX: Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=54, Recruiting, Georgetown University | Trial completion date: Jan 2027 --> Jun 2027 | Trial primary completion date: Jan 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Opdivo (nivolumab) • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    27d
    Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial (clinicaltrials.gov)
    P2, N=17, Active, not recruiting, Mayo Clinic | Trial primary completion date: Nov 2027 --> Feb 2026
    Trial primary completion date
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    lenalidomide • carfilzomib • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Hemady (dexamethasone tablets) • dexamethasone injection